Roberto Mazzanti, M.D
Professor of Medical Oncology


1974, July 25th M.D University of Florence, Italy
1979 Postgraduate School in Gastroenterology -
1981-1993 Senior Researcher School of Medicine , University of Florence, Department of Internal Medicine, Liver Unit


Born in Florence, Italy, 1949, he attended Medical and Postgraduate School in University of Florence becoming M.D. and Specialist in Gastroenterology. Lieutenant in the Italian Army as Medical Doctor. After that service he have been working at University Hospitals of Parma and Florence, on liver diseases and cancer for almost his career. Appointed Full Professor of Medicine, he have been teaching Internal Medicine to medical, nurse and technician students for many years and, subsequently, he had the Chair of Medical Oncology that he kept at the University of Florence to December 2013 when retired and moved to USA.
The President of the Repubblica Italiana appointed him Ufficiale (Officer) of the Ordine al Meritodella Repubblica Italiana.

He is acting as referee for many international journal such as: Hepatology, Gut, Oncogene, International J. of Cancer, Biochem. Pharmacol., Word J. Gastroenterology and others.

Research Interest

Research career of R.M. has concerned pathophysiology of the liver, gastrointestinal diseases and in the last 20 years his interests as scientist have moved to cancer and particularly to the understanding of how cancer cells become resistant to anticancer drugs and to ionizing radiation. In addition, he had been working on treatment of liver cancer and proteomics of colon cancer.
The most recent interests concern the effect of the acquiring of the multiple drug resistance (MDR) phenotype of cancer cells on mechanisms of cell resistance to several damaging agents and the relationship between MDR phenotype and cancer angiogenesis.
Main interests of research have been the important issue concerning drug resistance and cancer and liver diseases. Concerning this topics he have discovered that the expression of the MDR1 phenotype in cancer cells is associated with the expression of P-glycoprotein also in mitochondria membrane focusing on these important organelles as playing a central role in affecting drug sensitivity to anticancer drugs.

As regards primary liver cancer or hepatocellular carcinoma, he has accumulated during his career a long practice on how dealing with such lethal disease, that commonly it is associated with liver cirrhosis. He studied mechanisms by which hepatitis C infection can increase the risk for HCC in humans by triggering liver angiogenesis in addition to well known consequences of chronic inflammation such as necrosis, fibrosis and liver regeneration.

Scientific Activities

Awards and Experience Abroad:

  • Roberto Mazzanti, won a Welcome Trust Fellowship and between November 1984 to April 1986 worked at the Royal Free Hospital , London, UK, with Prof. Dame Sheila Sherlock first and Prof. Neil McIntyre then.
  • In 1988 he spent near 10 months at Tufts University, Boston, MA, working with Prof. Irwin M. Arias. In this period of time he was awarded with the Annual Prize for Research by the American Liver Foundation for his studies on the multi drug resistant phenotype in cancer cells (Chicago, November 5th, 1988).

Academic career

1974, July 25th M.D University of Florence, Italy
1979 Postgraduate School in Gastroenterology -
1981-1993 Senior Researcher School of Medicine , University of Florence, Department of Internal Medicine, Liver Unit
1993-1996 Associate Professor of Medicine School of Medicine, University of Parma, Internal Medicine
1996-2001 Associate Professor of Medicine School of Medicine, University of Florence, Internal Medicine
2001- now Full Professor of Medicine School of Medicine, University of Florence, Internal Medicine
2008 now Full Professor of Medical Oncology -
October 2002 Director of the Post Graduate School in Oncology University of Florence
2001 – 2013 Full Professor Medicine, Chair of Medical Oncology
2008 up to 31st December, 2013 Director of 2nd Unit of Oncologia Medica of Azienda Ospedaliero Universitaria Careggi


  1. Gentilini P., Laffi G.,Stefani P., Masi R., Buzzelli G., Salvadori G., Mazzanti R.e Moggi A.: Early functional modifications of the kidney in chronic hepatitis. In: Gentilini P., Popper H., Teodori U.(Eds.): ChronicHepatitis. pagg.69-76, Karger, Basilea, 1976. (senza IF)
  2. MazzantiR.., Arcangeli A., Salvadori G., Smorlesi C., Di Perri T., Auteri A., Boggiano C.A., Pippi L., Toti M., BOncompagni P., Angioli D., Caremani M., Magnolfi F., Camarri E., Motta R., Forconi A., Candidi Tommasi A., Lomi M., e Soldi A.: On the anti-steatosic' effects of S-adenosyl-methionine in variouschronicliverdiseases. Multicentrestudy. Curr.Ther.Res., 25:25-34, 1979. (IF:0,791)
  3. ChiarantiniE., Arcangeli A., Mazzanti R., Romagnoli P., Moscarella S. e Gentilini P.: Ethynil-estradiolinducedcholestasismorphological and functionalaspects. In: Gentilini P., Popper H., Sherlock S., Teodori U.(Eds.): Problems in intrahepatic cholestasis.pagg.102-110, Karger, Basilea, 1979. (senza IF)
  4. Gentilini P., Laffi G., Buzzelli G.,Cappelli G., Stefani P., Smorlesi C., La Villa G. e Mazzanti R.: Functional renal alterations' in intrahepatic cholestasis. In. Gentilini P., Popper H., Sherlock S., Teodori U.(Eds.): Problems in intrahepatic cholestasis. pagg.125-131, Karger, Basilea, 1979. (senza IF)
  5. ChiarantiniE., Mazzanti R., Chieca R., Orlandini F., Arena U., Coletta D. e Gentilini P.: Patogenesis and reboundphenomenon in ethynil-estradiolcholestasis in rats. Agressologie, 23:25-28, 1982. (senza IF)
  6. Giusti G., Ruggiero G.,Galanti B., Piccinino F., Sagnelli E., Gallo G., Arico' S., Bellei M., Bernardi M., Chiaramonte M., Colombo M., Del Ninno E., Iannuzzi C., Maio G., Manenti F., Marzillo G., Martinez D., Mastroroberto L., Mazzanti R., Pagliaro L., Pinzello G., Sacchi G., Schiraldi O., Tolentino P., Zancan L.: Chronicactivehepatitis in Italy: a multicentricstudy of clinical and laboratory data of 1154 cases. Hepatogastroenterol., 30:126-130, 1983. (IF:0,833)
  7. Moscarella S., Laffi G., Buzzelli G., Mazzanti R., Caramelli L. eGentilini P.: Expiredhydrocarbons in patients with chronicliverdisease. Hepatogastroenterol., 31:60-63, 1984.(IF:0,833)
  8. Giusti G., Piccinino F.,Galanti B., Sagnelli E., Ruggiero G., Gallo G., Arico' S., Bellei M., Bernardi M., Chiaramonte M., Colombo M., Del Ninno E., Iannuzzi C., Maio G., Manenti F., Marzillo G., Martinez D., Mastroroberto L., Mazzanti R., Pagliaro L., Pinzello G., Sacchi G., Schiraldi O., Tolentino P., Zancan L.: Immunosuppressivetherapy in chronicactivehepatitis. a multicentricretrospectivestudy on 867 patients. Hepatogastroenterol., 31:24-29, 1984. (IF:0,833)
  9. Buzzelli G., ChiarantiniE., Mazzanti R.Arcangeli A., Orioli S. e Gentilini P.: The BSF loading test in chronic alcoholic liver diseases. Boll.Soc.It.Biol.Sper., 60:543-548, 1984. (senza IF).
  10. Bechi P.,Carcangiu M.L. , Mazzanti R., Pacini P. Romagnoli P. e Tonelli L.: An insightinto post-gastrectomy "alkalinerefluxgastritis". Ital.J.Surg.Sci., 16:85-92, 1986. (senza IF).
  11. Bechi P., Mazzanti R., ArenaU., Gregorini M., Naspetti R. é Arcangeli G.: Bile acid pattern in gastricjuice and gallstonesafterpartialgastrectomy. I.R.C.S.Med.Sci., 14:130-131, 1986. (senza IF)
  12. Buzzelli G., Smorlesi C.,Mazzanti R., Pampana A., Matassi L., Simondi P. e Gentilini P.: Chemotherapy of primary and secondarylivercancer: isitusefull? Chemioterapia, 5:173-176, 1986. (senza IF).
  13. ChiarantiniE., Mazzanti R., Buzzelli G., Chieca R., Coletta D., Orlandini F., Romeo D. e Arena U.: Action of acute ethanolintake on ratbiliarysecretion. Effect of epomediol. Il Farmaco, 41:307-312,1986. (senza IF)
  14. Mazzanti R.,Chiarantini E., Arena U., Moscarella S. e Buzzelli G.: Can serum bile acid determinationsubstitute BSP loading test in detecting and monitoringchronicliverdisease? Boll. Soc.It. Biol. Sper., 62:219-226, 1986. (senza IF)
  15. Moscarella S., Chieca R.,Mazzanti R.Chiarantini E., Zignego A.L. e Gentilini P.: Glutathionelevels in drinkers' livers. Front. Gastrointest. Res., 9:158-166, 1986. (senza IF)
  16. Mazzanti R. , Jenkins W.J.: Effect of chronic ethanol intake on the enterocyte turnover in rats. Gut, 28:52-55, 1987. (IF:6,323)
  17. Mazzanti R., Debnam E.S., Jenkins W. J.: Effect of chronic ethanol intake on lactase activity and active galactose absorption in rat small intestine. Gut, 28:56-60, 1987.(IF:6,323)
  18. Mazzanti R.Srai K.S., Debnam E.S., Boss A.M. and Gentilini P.: The effect of chronic ethanol consumption on iron absorption in rats. Alcohol and Alcoholism, 22:47-52, 1987.(IF:1,816)
  19. The Italian Liver Cirrhosis Project: Pagliaro L., Spina G.P.,...Mazzanti al.: Reliability of endoscopy in the assessment of variceal features. J. Hepatol., 4:93-98, 1987. (IF: 4,974)
  20. Bechi P.,Amorosi A., Mazzanti R., Romagnoli P. and Tonelli L.: Gastric histology and fasting bile reflux after partial gastrectomy. Gastroenterology, 93:335-343, 1987.(IF:13,440)
  21. Gentilini P.,Mazzanti R., Buzzelli G., Baronti E., Gialdini D. et al. Alcoholicliverdisease in Tuscany. Preliminary results of a multicentre study. Ital. J. Med., 3:83-87, 1987. (senza IF).
  22. Bechi P., Mazzanti R.,Castagnoli A., Arena U., Naspetti R. and Buccarelli A.: Enterogastricrefluxdetected by cholescintigraphy. Assessment of bile acids in gastric aspirates, and gastric pH monitoring: Comparison of results in partially gastrectomized patients. In: Siewert J.R. and Holscher A.H. (Eds.): Dis Esophagus. 1299-1303, 1088. (IF:0,603)
  23. Carini R.,Mazzanti R, Biasi F., Chiarpotto E., Marno G., Moscarella S., Gentilini P., Dianzani M.U. and Poli G.: Fluorescentaldehyde-proteinadducts in the bloodserum of healthyalcoholics. Advances in the Biosciences, 71:61-64.1988. (senza IF)
  24. MazzantiR., Pinzani M., Zignego A.L., Buzzelli G., Romanelli R.G., Foschi M., Galaska R. and Gentilini P.: Effects of recombinant human gamma-interferon on advanced hepatocellular carcinoma. In: Gentilini P., Dianzani M.U.( Eds.): Pathophysiology of the liver,pagg. 227-235, Excerpta Medica, Amsterdam, 1988. (senza IF)
  25. Bechi P., Amorosi A.,Mazzanti R.Buccarelli A., Pantalone D. and Cortesini C.: Short-term effects of bile diversion on the postgastrectomy gastric histology. Dig. Dis. Sci., 33:1288-1296, 1988. (IF:1,303)
  26. Bechi P., Naspetti R., Mazzanti R., Castiglione G., Tonelli P., Amorosi A., Tonelli L.: Billroth I versus Billroth II partial gastrectomy in thetreatmentofgastriculcer. It. J.Surg. Sci., 18:339-346, 1988. (senza IF)
  27. Mazzanti R., Moscarella S., Bensi G., Altavilla E. and GentiliniP.: Hepatic lipid peroxidation and aldehyde dehydrogenase activity inalcoholic and non alcoholic liver disease. Alcohol and Alcoholism,24, 121-128, 1989. (IF:1,816)
  28. MazzantiR., Caramelli L., Georgudis E., Moscarella S. and Gentilini P.: Effect of chronic alcoholism on hepatic alcohol- and aldehyde-dehydrogenase activities in man. Boll. SocIt.Biol. Sper. LXV, 465-472, 1989. (senza IF)
  29. Moscarella S., Mazzanti R.,Gentilini P.: Role of lipid peroxidation and antioxidant in alcoholic liver disease in man. In:Poli G., Cheeseman K.H., Slater T.F., Dianzani M.U. (Eds) "Free Radicals in Liver Pathology" . Advances in the Biosciences, vol. 76;pp. 275-280, 1989. Pergamon Press, Oxford. (senza IF)
  30. Al Balool F., Debnam E.S. andMazzanti R.: Acute and chronic exposure to ethanol and the electrophysiology of the brush border membrane of rat small intestine. Gut, 30, 1698- 1703, 1989. (IF:6,323)
  31. Moscarella S.,Buzzelli G., Mazzanti R.and Gentilini P. Lipoperoxidative processes and antioxidants in chronic liver disease in different age groups. In: The liver, metabolism and ageing Woodhouse K.W., Yelland C., James O. F., W. Eds. 1989; pag. 151- 160. (senza IF)
  32. MazzantiR.,Gatmaitan Z., Croop J. M., Shu H. and Arias I.M Quantitative image analysis of rhodamine 123 transport by Adriamycin-sensitive and resistant NIH 3T3 and human hepatocellular carcinoma (Alexander) cells. J. Cell Pharmacol. 1; 50-56; 1990. (senza IF)
  33. Mazzanti R., Moscarella S. and Gentilini P. Chronic alcohol abuse, lipid peroxidation and liver damage in man. In: Advances in Free Radicals in disease II. Tomasi A., Ursini F., Vannini V.; Eds. CLEUP Ed. Padova. pp 193-198; 1990. (senza IF)
  34. Bechi P., Balzi M., Becciolini A., Amorosi A., ScublaE., V., Mazzanti R., Tonelli P., and Cortesini C. Gastric cell proliferation kinetics and bile reflux after partial gastrectomy. The Am. J. Gastroenterol. 86; 1424-1432; 1991. (IF: 3,953)
  35. Arias I.M., Gatmaitan Z., Mazzanti R., Shu H., Kumamoto Y. Structure and function of P-glycoprotein in the normal liver and intestine. In: Xenobiotics and Cancer. L. ErnsterEdt ., Taylor and Francis LTD. London , 1991:pag 229-239. (senza IF)
  36. Lippi G., Fedi S., Grassi M., Rosi E., Alessandriello Liotta A., Fontanelli A., Cella A.P., Mazzanti R.. Acute phase proteins in alcoholics with or without liver injury. It. J. Gastroenterol. 24; 383-385, 1992. (IF: 0,589)
  37. Mazzanti R., Croop JM, GatmaitanZ., Budding M., Steiglitz K., Arceci R. and Arias IM. Benzquinamide inhibits P-glycoprotein mediated drug efflux and potentiates anticancer agent cytotoxicity in multidrug resistant cells. Oncology Res. (già CancerCommun.) 4; 359-365, 1992. (IF:1,476)
  38. Bechi P., Amorosi A., Mazzanti R., Dei R., Bianchi S., Mugnai L.,Masini E. Reflux related gastric mucosal injury is associated with increased mucosal histamine content in humans. Gastroenterology, 104; 1057-1063, 1993. (IF:13,440)
  39. Bechi P.,Pucciani F., Baldini F., Cosi F., Falciai R., Mazzanti R. et al., Long-termambulatoryenterogastricrefluxmonitoring. Validation of a new fiberoptictechnique. Dig. Dis. Sci.38; 1297-1306, 1993. (IF: 1,438)
  40. Monsacchi L., and Mazzanti R. Epidemiologia e historianatural del carcinoma hepatico. ReviewArticle. Rev.Cancer (Madrid)(Spagnolo). 7:29-33; 1993. (senza IF)
  41. Mazzanti R. La colestasi intraepatica: aspetti clinici e cenni di terapia. Gastroenterology and Hepatology 1/93; 21-23; 1993. (senza IF).
  42. Mazzanti R., Monsacchi L., and Gentilini P., Epidemiology and natural history of hepatocellular carcinoma. Review Article. Forum, Trends in Exp. &Cli. Med. 4: 161-171; 1994. (senza IF)
  43. Zignego A.L., Foschi M., Laffi. G., ... Mazzanti R. et al. “Inapparent” hepatic B virus infection and hepatitis C virus replication in alcoholic subjects with and without liver disease. Hepatology ,19; 577-582; 1994. (IF:9,825)
  44. Mazzanti R., Fantappié O., Fabrizio P., Monsacchi L., Gentilini P. Effect of the induction of multiple drug resistance on susceptibility to lipid peroxidation in a human hepatocellular carcinoma cell line. In Advances in Free Radicals in disease. Tomasi A., Ursini F., and Vannini V. Eds. CLEUP Edizioni, Padova, pagg. 159-166; 1994. (senza IF)
  45. Mazzanti R., Fantappiè O., Kamimoto Y, Gatmaitan Z., Gentilini P., and Arias I.M. Bile acid inhibition of P-glycoprotein mediated transport in multidrug resistant cells and rat liver canalicular membrane vesicles. Hepatology, 20:170-176; 1994. (IF:9,825)
  46. Mazzanti R. Treatment of hepatocellular carcinoma. Review Article. AlpeAdria J. Med. 49:651-661; 1994. (senza IF).
  47. Gentilini P., Romanelli R.G., Foschi M., Mazzanti R.Pathogenetic mechanisms of intrahepatic cholestasis. In: Fat storing cells and Liver fibrosis. Surrenti C., Casini A., Milani S., Pinzani M. Eds. KluweracademicPublishers, Dordrecht;Falk 71: 279-303; 1994. (senza IF)
  48. Mazzanti R., Fantappiè O., Fabrizio O., and Relli P. Susceptibility to lipid peroxidation of human hepatocellular carcinoma cell lines with different levels of multiple drug resistant phenotype. Lab. Invest. 73:419-423; 1995. (IF:4,0)
  49. Mazzanti R., FantappièO., Fabrizio O., Pacini S., Relli P., Casamassima F., Milano F. and Ruggiero M. Conferringdrugresistance by MDR1 gene transfectionincreasessusceptibility to irradiation and lipidperoxidation in 3T3 cell line. FreeRad. Biol. &Med. 20:601.606; 1996. (IF:5,533)
  50. Mazzanti R, Fantappié O., Fabrizio P. The effect of development of the MDR1 phenotype on cell susceptibility to undergoing lipid peroxidation and ionizing radiation. In: New Trends in Hepatology. Gentilini P, and Dianzani MU. Eds. KluwerAcademicPublishers, Dordrecht, pgg 65-73; 1996. (senza IF)
  51. P. Gentilini,Laffi G., Romanelli RG, Buzzelli G, Casini Raggi V., Melani L., .Mazzanti R., et al.Clinical course and prognostic elements of virus induced liver cirrhosis in Italian patients. The Am. J. Gastroenterology 92:66-72; 1997. (IF:3,953)
  52. Mazzanti R., Messerini L., Monsacchi L, Buzzelli G, Zignego AL, Foschi M, Monti M, Laffi G,et al. Chronic viral hepatitis induced by HCV but not HBV infection correlates with increased liver angiogenesis. Hepatology, 25:229-234; 1997. (IF:9,825)
  53. R. Duranti, G. Laffi, G. Misuri,D. Riccardi, M. Gorini, M. Foschi, I. Iandelli, R. Mazzanti, M. Mancini, G. Scano, P. Gentilini. Respiratory mechanics in patients with tense cirrhotic ascites. EurRespJ 10:1622-1630; 1997. (IF :2,931)
  54. The CLIP group (Cancer of the Liver Italian Group) C. Gallo…..P. Gentilini, R. Mazzanti, et al..Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. The Lancet, 352; 17-20; 1998. (IF:15,397)
  55. T.Stroffolini, P. Andreone, A. Andriulli, ..R. Mazzanti, et al. Characteristics of hepatocellular carcinoma in Italy. J. Hepatol. 29; 944-952; 1998. (IF: 4,974)
  56. T.Stroffolini, P. Andreone, A. Andriulli, ..R. Mazzanti, et al.. Gross pathologic types of hepatocellular carcinoma in Italy. Oncology, 56; 189-192; 1999. (IF:2,330)
  57. The CLIP group, F. Perrone, B. Daniele, R. Mazzanti, et al…Prospective validation of the CLIP score, a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology, 31, 840-845, 2000. (IF:9,825)
  58. Bechi, P., Cianchi, F., Mazzanti R., Fantappié, O., Fiorillo, C., Nassi, P. Reflux and pH:”alcaline” components are not neutralized by gastric pH variations. Dis. Esophagus. 13; 51-55; 2000. (IF:0,603 )
  59. B. Neri, G. Cini, F. Andreoli, B. Boffi, D. Francesconi, R. Mazzanti, F. Medi., A. Mercatelli, S. Romano, L. Siliani, R. Tarquini, and R. Moretti. Randomised trial of adjuvant chemotherapy versus control after curative resection for gastric cancers:5-year follow-up. B. J.Cancer84; 878-880; 2001. (IF:3,639)
  60. E. Masini, O. Fantappié, I. Sardi, L. Raimondi, V. Fabbroni, PFMannaioni, and R. Mazzanti Lipid peroxidation and cyclooxygenase-2 activity in human hepatocellular carcinoma cell lines with and without multiple drug resistance:correlation with cell growth.. In :Advances in Prostaglandin and Leukotriene Research, Edited by Samuelsson B., Paoletti R., Folco GC, Granstrom E. and Nicosia S. Kluwer Academic Publishers, Dordrecht, 2001; pagg. 183-186.
  61. Cianchi F., Cortesini C., Bechi P., Fantappiè O., Messerini L., Vannacci A., Sardi I., Baroni G., Boddi V., Mazzanti R., Masini E. Up – regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology, 121; 1339-1347; 2001. (I.F.: 13.440)
  62. FomusiNdisangJ., Wang R., Vannacci A., Marzocca C., Fantappié O., Mazzanti R.,Mannaioni PF. And Masini E. haeme oxygenase-1 as a novel target in the modulation of cardiac anaphylaxix. Brit J Pharmacol ,134; 1689-1696, 2001. (I.F:3,450)
  63. FantappiéO., Masini E., Sardi I., Raimondi L., Bani D., Solazzo M., Vannacci A. and Mazzanti R. The multiple drug resistance phenotype is associated with the expression of COX-2 and iNOS in human hepatocellular carcinoma cell line. Hepatology35(4):843-52; 2002.(I.F.:9.825)
  64. Perrone F., Gallo C, Daniele B, … Mazzanti R. et al. Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of the CLIP-1 multicentre randomised controlled trial. Curr Pharm Des.8 (11):1013-9; 2002. (I.F:4,692).
  65. Cianchi F., Cortesini, C., Fantappié O, Mazzanti R., et Al. Inducible nitric oxide synthase expression in human colorectal cancer: correlation with tumor angiogenesis. Am J Pathol.162;793-801; 2003 (IF:6,750).
  66. Masini E., Vannacci A., ....Mazzanti R. et al. Heme oxygenase-1 and the ischemia-reperfusion injury in the rat heart. ExpBiol Med (Maywood). May;228(5):546-9; 2003. ( IF: 2,460)
  67. Daniele B., De Sio I., Izzo F.,...................Mazzanti R. et al. (CLIP Investigators) Hepatic
  68. resection and Percutaneous ethanol injiection as tttreatments of small hepatocellular carcinoma: a cancer of the Italian Liver Program (CLIP 08) retrospective case-control study. J.ClinGastroenterol36; 63-67; 2003.(IF:1,357).
  69. Mazzanti R., Giallombardo AL, Mini E., et al......... Treatment of locally advanced hepatocellular carcinoma with intra hepatic artery chemotherapy: a pilot study. Dig. LiverDis. 36(4); 278-285;2004. (IF:1,265)
  70. Cianchi F., Cortesini C., ...Mazzanti R. et al. Cyclooxygenase-2 activation mediates the pathogenic effect of nitric oxide in colorectal cancer. Clin Cancer Res. 10; 2694-2704; 2004. (IF:5,991).
  71. Vannacci A, Giannini L., ...Mazzanti R. et al. The endocannabinoid 2-arachidonylglycerol decreases the immunological activation of Guinea pig mast cells: involvement of nitric oxide and eicosanoids. J PharmacolExpTher. Oct;311(1):256-64. 2004. (IF:4,337)
  72. Fantappiè O., Lodovici M., ..Mazzanti R. Vitamin E protects DNA from oxidative damage in human hepatocellular carcinoma cell lines. Free Radic Res. Jul;38(7):751-9; 2004. (IF:2,743)
  73. Mazzanti R., Arena U., Pantaleo P., et al... Survival and prognostic factors in patients with hepatocellular carcinoma treated by percutaneous ethanol injection: A 10-year experience. Can J Gastroenterol. Oct;18(10):611-8; 2004. (IF:1,265).
  74. Cipriani G, Mazzanti R. Treatment with inhibitors of angiogenesis in advanced hepatocellular carcinoma: a new tool in our hand or simply a hope? . Dig. Liver Dis. 37; 230-231; 2005 (IF 1,265).
  75. Fulignati C., Pantaleo P., Cipriani G, Turrini M. Nicastro R., Mazzanti R.,Neri B. An uncommon clinical presentation of retroperitoneal non Hodgkin lymphoma successfully treated with chemotherapy: a case report. World J Gastroenterol 28; 3151-3155; 2005 (IF: 3).
  76. Darja Kanduc1*, JanGeliebter, Alberta Lucchese, Roberto Mazzanti, …………, Emanuel Farber. Gene therapy in cancer: the missing point. Journal of Experimental Therapeutics and Oncology, Vol. 5, pp. 151-158, 2005.
  77. Roberto Mazzanti ,Solazzo Michela, SquiresRachel, Fantappiè Ornella, Elfering Sarah, Pantaleo Pietro, Bechi Paolo, Cianchi Fabio, and Giulivi Cecilia. Identification of potential target proteins in human colon cancer through expression proteomics. AmJ.Physiol, GastrointestLiverPhysiol 2006Jun;290(6):G1329-38.. (IF:3,479).
  78. Lasagna Nadia, Ornella Fantappiè, Michela Solazzo, Lucia Morbidelli, Serena Marchetti, Greta Cipraini, Marina Ziche and Roberto Mazzanti. Hepatocyte Growth Factor and Inducible Nitric Oxide Synthase are Involved in Multiple Drug Resistance-Induced Angiogenesis in Hepatocellular Carcinoma Cell Lines, Cancer Res, 2006Mar 1;66(5):2673-82. (IF: 7,69)
  79. Neri B., Vannozzi L, …Mazzanti R. Long-term survival in metastatic melanoma patients treated with sequential biochemotherapy: report of a Phase II study.Cancer Invest. 2006 Aug-Sep;24(5):474-8. (IF 2,335)
  80. Solazzo M., FantappièO ….Mazzanti R. P-glycoprotein localization in mitochondria and its functional characterization in multiple drug resistant cell lines. Exp Cell Res 2006;312: 4070-4078.(IF:4,148)
  81. Roberto Mazzanti ,Solazzo Michela, SquiresRachel, Fantappiè Ornella, Elfering Sarah, Pantaleo Pietro, Bechi Paolo, Cianchi Fabio, and Giulivi Cecilia. Identification of potential target proteins in human colon cancer through expression proteomics. AmJ.Physiol, GastrointestLiverPhysiol 2006Jun;290(6):G1329-38.. (IF:3,479).
  82. Lasagna Nadia, Ornella Fantappiè, Michela Solazzo, Lucia Morbidelli, Serena Marchetti,Greta Cipriani, Marina Ziche and Roberto Mazzanti. HepatocyteGrowthFactor andInducibleNitricOxideSynthase are Involved in Multiple DrugResistance-InducedAngiogenesis in Hepatocellular Carcinoma Cell Lines,Cancer Res, 2006Mar 1;66(5):2673-82. (IF: 7,616)
  83. Mazzanti RobertoandGiulivi Cecilia Coordination of nuclear and mithocondrial –DNA encoded proteins in cancer and normal colon tissues.BiochimBiophysActa, 2006 May – Jun; 1757(5-6):618-23. (IF: 4,302)
  84. Bolondi L,Piscaglia P…..Mazzanti R. et al. Effect of Potassium Canrenoate, an Anti-aldosterone Agent, on Incidence of Ascites and Variceal Progression in Cirrhosis. ClinGastroenterolHepatol.2006 Aug 21;1395-1402.
  85. Oostendorp RL, Marchetti S., Bejinen JH ,Mazzanti R., Schellens JH. The effect of hydroxyurea on P-glycoprotein/BCRP-mediated transport and CYP3A metabolism of imatinibmesylate.Cancer ChemotherPharmacol. 2007 May;59(6):855-60. [Epub ahead of print] (IF:2,235)
  86. FantappièO., Solazzo M., Lasagna N., Platini F., Tessitore L, Mazzanti R.P-glycoprotein mediates celecoxib-induced apoptosis in multiple drug resistant cell lines. Cancer Res 2007 ;67:4915-4923; (IF:7,616)
  87. Marchetti S, Mazzanti R, Beijnen JH, Schellens JH.Concise review: Clinical relevance of drug-drug and herb - drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein).Oncologist. 2007 Aug;12(8):927-41. (I.F.=5,206)
  88. Mazzanti R, Messerini L, Comin CE, Fedeli L, Ganne-Carrie N, BeaugrandM.Liver angiogenesis as a risk factor for hepatocellular carcinoma development in hepatitis C virus cirrhotic patients.World J Gastroenterol. 2007 Oct 7;13(37):5009-14. (I.F=3,318)
  89. Fantappiè O., Lasagna N. Solazzo M., Neri B., and Mazzanti R. The multiple drug resistance phenotype and its consequences for cell biology of cancer cells. Res. Adv. In Cancer, 7; 127-137; 2007.
  90. Marchetti S., Mazzanti R.,Beijnen JH, and Schellens JM. Clinical relevance:drug-drug interaction,pharmacokinetics, pharmacodynamics and toxicity. In: Drug Transporters, Molecular Characterization and Role in Drug Disposition. Edited by: Guofeng You and Marilyn E. Morris. Wiley InterScience, Wiley &Sons Inc., Publication, pag. 747-880; 2007.
  91. Marchetti S, Oostendorp RL, Pluim D, van Eijndhoven M, van Tellingen O, Schinkel AH, Versace R, Beijnen JH, Mazzanti R, Schellens JH. In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2. Mol Cancer Ther. 2007 Dec;6(12):3307-13. (IF:5,135).
  92. Mazzanti R, Gramantieri L, Bolondi L. Hepatocellular carcinoma: Epidemiology and clinical aspects. Mol Aspects Med. 2008 Feb-Apr;29(1-2):130-43. (IF:7,386)
  93. Marchetti S, de Vries NA, Buckle T, Bolijn MJ, van Eijndhoven MA, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JHEffect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.Mol Cancer Ther. 2008 Aug;7(8):2280-7 (IF:5,135).
  94. Mazzanti R, a,*, Francesca Platinib, Consuelo Bottinib, OrnellaFantappie` a, MichelaSolazzoa, Luciana Tessitoreb. Down-regulation of the HGF/MET autocrine loop induced by celecoxib and mediated by P-gp in MDR-positive human hepatocellular carcinoma cell line. BiochemParmacol2009; 78; 21-32(IF: 4.838).
  95. Solazzo M, Fantappiè O, D'Amico M, Sassoli C, Tani A, Cipriani G, Bogani C, Formigli L, Mazzanti R. Mitochondrial expression and functional activity of breast cancer resistance protein in different multiple drug-resistant cell lines.Cancer Res. 2009 Sep15;69(18):7235-42. Epub 2009 Aug 25. (I.F.= 7,514).
  96. Kanduc D, Novello G, Mazzanti R.P-170 peptides with low similarity to the human proteome: tracing an effective and safe biological way towards effective and safe cancer chemotherapy.J ExpTherOncol. 2009;8(2):151-5.
  97. Baldazzi V, Tassi R,Lapini A, Santomaggio C, Carini M, Mazzanti R. The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: A prospective single-center study. UrolOncol. 2012 Sep; 30(5) 704-710(IF= 2.53).
  98. Sunitinib-induced hyperparathyroidism: A possible mechanism to altered bone homeostasis.Baldazzi V, Tassi R, Lapini A, Lunghi A, Garofoli E, Caruso S, Carini M, Mazzanti R. Cancer. 2012 Jun 15; 118 (12) 3165-3172. doi: 10.1002/cncr.26435. (I.F.= 5.131).
  99. Marchetti S, Pluim D, van Eijndhoven M, van Tellingen O, Mazzanti R,Beijnen JH, Schellens JH.Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA. Invest New Drugs. 2013 Oct; 31(5):1125-1135. Doi 10.1007/s10637-013-9923-1.


Autoimmune Journal Flyer